CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.02M, lower than 95% of all stocks globally
- PositionOperating margin is -5698.8%, lower than 95% of its Biotechnology peers (median -23.8%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.53BUSDvs all stocks (USD)
Revenue (TTM)
4.01MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.07xvs all stocks
52-Week Change
106.28%vs all stocks
Market Capitalization
2.53BUSDvs all stocks (USD)
Enterprise Value
1.95BUSDvs all stocks (USD)
Forward P/E
-10.53xvs Biotechnology peers
Price to Book (MRQ)
4.29xvs Biotechnology peers
Enterprise to Revenue
485.37xvs Biotechnology peers
Enterprise to EBITDA
-8.61xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-29.72%vs Biotechnology peers
Return on Equity (TTM)
-50.14%vs Biotechnology peers
Revenue (TTM)
4.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0420USDUpdated Jul 19, 2026Gross Profit (TTM)
-182.78MUSDvs all stocks (USD)
EBITDA (TTM)
-226.35MUSDvs all stocks (USD)
Net Income (TTM)
-224.59MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-196.50MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-139.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
6.94MUSDFY2025 · Dec 31, 2025Operating Income
-224.11MUSDvs all stocks (USD)
Pre-tax Income
-212.39MUSDFY2025 · Dec 31, 2025Net Income
-212.39MUSDFY2025 · Dec 31, 2025EBIT
-224.11MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-221.16MUSDFY2025 · Dec 31, 2025Research & Development
187.29MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
43.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.72MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.43USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.43USDFY2025 · Dec 31, 2025Basic Shares Outstanding
87.35MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
87.35MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-212.39MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-190.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-199.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
653.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-212.39MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.96MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.69MUSDFY2025 · Dec 31, 2025Other Non-cash Items
10.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-9.16MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.69MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-6.25MUSDFY2025 · Dec 31, 2025Purchase of Investments
-123.27MUSDFY2025 · Dec 31, 2025Sale of Investments
200.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
67.05MUSDFY2025 · Dec 31, 2025Other Financing Charges
-39.46MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
639.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
113.17MSharesUpdated Jul 19, 2026Float Shares
108.31MSharesUpdated Jul 19, 2026Shares Short
17.37MSharesUpdated Jul 19, 2026Short Ratio
9.79daysvs all stocks
Short % of Shares Outstanding
17.94%vs all stocks
% Held by Insiders
6.30%vs all stocks
% Held by Institutions
108.42%vs all stocks
Total Cash (MRQ)
582.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.14USDUpdated Jul 19, 2026Total Debt (MRQ)
3.69MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0063xvs Biotechnology peers
Current Ratio (MRQ)
21.68xvs Biotechnology peers
Book Value per Share (MRQ)
5.20USDUpdated Jul 19, 2026Total Assets
683.19MUSDvs all stocks (USD)
Total Current Assets
660.78MUSDFY2025 · Dec 31, 2025Total Liabilities
48.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.41MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
44.99MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
653.48MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Payable
3.34MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
3.63MUSDFY2025 · Dec 31, 2025Long-term Debt
3.85MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-728.16MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
634.34MUSDvs all stocks (USD)
52-Week Low
8.66USDUpdated Jul 19, 202652-Week High
27.65USDUpdated Jul 19, 202652-Week Change
106.28%vs all stocks
Beta
2.07xvs all stocks
50-Day MA
21.07USDUpdated Jul 19, 2026200-Day MA
20.49USDUpdated Jul 19, 2026Avg 10-Day Volume
1.45MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.67MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.39USDUpdated Jul 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5698.8%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -56.99Industry median: -0.24Industry P5: -32.91Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.02M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,015,000Global P5: 30,274,777.221
Market cap is $2.53B, above the global median of $1.15BNotable
Market cap (USD): 2,527,748,794Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Gansu Engineering Consulting Group Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Inhibikase Therapeutics Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Iovance Biotherapeutics, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC